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Abstract
Background: The marine n-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) exert
numerous beneficial effects on health, but their potency to improve treatment of type 2 diabetic (T2D) patients
remains poorly characterized. We aimed to evaluate the effect of a combination intervention using EPA + DHA
and the insulin-sensitizing drug pioglitazone in overweight/obese T2D patients already treated with metformin.
Methods: In a parallel-group, four-arm, randomized trial, 69 patients (66 % men) were assigned to 24-week-intervention
using: (i) corn oil (5 g/day; Placebo), (ii) pioglitazone (15 mg/day; Pio), (iii) EPA + DHA concentrate (5 g/day,
containing ~2.8 g EPA + DHA; Omega-3), or (iv) pioglitazone and EPA + DHA concentrate (Pio& Omega-3).
Data from 60 patients were used for the final evaluation. At baseline and after intervention, various metabolic markers,
adiponectin and cytokines were evaluated in serum using standard procedures, EPA + DHA content in serum
phospholipids was evaluated using shotgun lipidomics and mass spectrometry, and hyperinsulinemic-euglycemic
clamp and meal test were also performed. Indirect calorimetry was conducted after the intervention. Primary
endpoints were changes from baseline in insulin sensitivity evaluated using hyperinsulinemic-euglycemic
clamp and in serum triacylglycerol concentrations in fasting state. Secondary endpoints included changes in
fasting glycemia and glycated hemoglobin (HbA1c), changes in postprandial glucose, free fatty acid and
triacylglycerol concentrations, metabolic flexibility assessed by indirect calorimetry, and inflammatory markers.
Results: Omega-3 and Pio& Omega-3 increased EPA + DHA content in serum phospholipids. Pio and Pio&
Omega-3 increased body weight and adiponectin levels. Both fasting glycemia and HbA1c were increased by
Omega-3, but were unchanged by Pio& Omega-3. Insulin sensitivity was not affected by Omega-3, while it
was improved by Pio& Omega-3. Fasting triacylglycerol concentrations and inflammatory markers were not
significantly affected by any of the interventions. Lipid metabolism in the meal test and metabolic flexibility
were additively improved by Pio& Omega-3.
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Conclusion: Besides preventing a modest negative effect of n-3 fatty acids on glycemic control, the combination of
pioglitazone and EPA + DHA can be used to improve lipid metabolism in T2D patients on stable metformin therapy.
Trial registration: EudraCT number 2009-011106-42.
Keywords: Eicosapentaenoic acid, Docosahexaenoic acid, Indirect calorimetry, Meal test, Humans, Hyperinsulinemic-
euglycemic clamp
Background
The complex etiology of type 2 diabetes (T2D) prompts
for the use of a combination therapy to target multiple
underlying mechanisms. Indeed, standards of medical
care in diabetes recommend the combination therapy of
metformin and other anti-diabetic drugs, next to metfor-
min monotherapy [1]. Major effects of metformin include
the lowering of hepatic glucose production and fasting
glycemia and reduced risk of cardiovascular events [2],
as well as an independent anti-inflammatory action [3]
and amelioration of the oxidative stress [4]. The com-
bination of metformin and the peroxisome proliferator-
activated receptor (PPAR) γ agonist pioglitazone, a drug
from the thiazolidinedione family, provided superior
clinical outcomes to metformin alone [5]. In spite of
the beneficial effects of thiazolidinediones on glycemic
control, insulin sensitivity, inflammation and oxidative
stress [2, 4, 5], as well as their triacylglycerol-lowering
effect in both humans [5] and mice [6, 7], clinical use
of pioglitazone has declined recently due to the risk of
its side-effects (reviewed in [1, 8]). However, this risk
could be outweighed by the benefits of pioglitazone in
prevention of cardiovascular disease [9], the leading
cause of death in patients with T2D [10]. Indeed, pio-
glitazone is associated with a relatively low risk of all-
cause mortality (reviewed in [8]).
Dietary interventions represent an important part of
any management or treatment strategy for patients
with T2D. Naturally occurring long-chain n-3 polyun-
saturated fatty acids, namely eicosapentaenoic acid
(EPA; 20:5 n-3) and docosahexaenoic acid (DHA; 22:6
n-3), are considered to be healthy dietary constituents
in diabetics [11]. These fatty acids exert anti-inflammatory
and hypolipidemic effects, while increasing catabolism of
lipids via a PPARα-mediated mechanism [11, 12]. At a
daily dose of 4 g, EPA +DHA are approved for the treat-
ment of hypertriacylglycerolemia [13] and could amelior-
ate non-alcoholic fatty liver disease [14]. Even modest
consumption of EPA +DHA (0.25–0.5 g/day) helps to
prevent cardiovascular disease [15], reflecting probably
the stabilization of atherosclerotic plaques [16]. The hypo-
lipidemic effect of n-3 fatty acids could also be involved,
since increased postprandial triacylglycerolemia represents
an independent risk factor for cardiovascular disease in
T2D patients [10, 17]. In contrast with the earlier clinical
trials, most of the recent studies did not show a benefit
of EPA + DHA in the secondary prevention of cardio-
vascular disease (reviewed in [11]). Importantly, in
patients with T2D within a large cohort, positive car-
diovascular effects of n-3 fatty acids were observed
[18]. Regarding the effects of EPA + DHA on glycemic
control and insulin sensitivity, positive results have
been obtained in animal models (reviewed in [11]), and
in the prevention of T2D in obese children and young
overweight/obese individuals [19]. Mixed results were
obtained with respect to prevention of T2D by EPA +
DHA in adult humans; in patients with T2D, either no
or detrimental effects on glucose homeostasis were
found in older studies, while more recent studies
mostly showed neutral effects [11].
Our experiments in mice with diet-induced obesity
[6, 7, 20] demonstrated additive beneficial effects of a
combined intervention using EPA + DHA and thiazoli-
dinediones on insulin sensitivity, glucose tolerance,
metabolic flexibility, lipid metabolism, hepatic steato-
sis, inflammation and obesity. These effects were ob-
served in both the prevention [6, 7, 20] and reversal
[7] of obesity-associated phenotypes. Therefore, in this
study, we sought to examine whether EPA +DHA, at a
dose of ~2.8 g/day (i.e., 5 g EPA +DHA concentrate/day),
could modulate the effects of pioglitazone in over-
weight and obese patients with T2D, specifically in
well-controlled patients treated with metformin. In
order to unmask potential additive effects, pioglita-
zone was used at a relatively low dose of 15 mg/day,
which is the initial recommended dose for treatment.
The major goal of the study was to characterize the effect
of the combined intervention on glucose homeostasis and
lipid metabolism.
Materials and methods
Study design and patients
A 24-week, parallel-group, four-arm, randomized trial
(EudraCT number 2009-011106-42) was conducted in
accordance with the principles of the Declaration of
Helsinki (2008 revision) and with approval by the Insti-
tutional Ethical Committee. All patients provided writ-
ten informed consent prior to their participation.
Inclusion criteria were 40–70 years of age, diagnosis of
T2D as defined by the criteria of the American Diabetes
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Association and recognized by WHO, Expert Com-
mittee on the Diagnosis and Classification of Diabetes
Mellitus (American Diabetes Association, 2004) diagnosed
at least 3 months preceding screening visit, treatment
by oral metformin as a monotherapy at a stable dose
(0.5–3.0 g/day) for at least 1 month and no other an-
tidiabetic agent, hemoglobin A1c (HbA1c) < 80 mmol/
mol, fasting plasma triacylglycerols ≤ 6 mmol/l, BMI
25–45 kg/m2, ability and willingness to adhere to the
protocol and signed and dated written Informed con-
sent obtained before any trial-related activities. Exclu-
sion criteria were type 1 diabetes, uncorrected thyroid
dysfunction, significant weight gain or loss (>5 % of
total body weight within the past 3 months), therapy
with insulin, or warfarin or fibrates within past 3 months
(statins and salicylic acid were allowed; 51 % of patients
were treated with either simvastatin or atorvastatin),
tachycardia (>100 beats/min; or use of stable doses of anti-
hypertensives shorter than 3 months prior the screening
and during the trial), history of cardiovascular disease
(myocardial infarction in the last year, coronary revascu-
larization including percutaneous transluminal coronary
angioplasty, coronary artery bypass graft surgery in the
previous year and no subsequent angina, unstable angina,
congestive heart failure), pregnancy or lactation, signifi-
cant renal impairment (serum creatinine >150 μmol/l),
chronic or advanced hepato-biliary diseases, history of
alcohol or substance abuse within the past year, al-
lergy to any of the capsule excipients, participation in
any other clinical trial during the previous 3 months,
and clinically significant anemia (hemoglobin < 120 g/l
for males and < 110 g/l for females) or any other ab-
normal hemoglobin profile.
Procedures
Out of 294 patients subjected to an initial screening, 69
eligible patients (66 % men) were enrolled (Fig. 1) at the
Diabetes Centre, Institute for Clinical and Experimental
Medicine, Prague, Czech Republic. All measurements,
procedures and sample collection were performed at
week 0 and week 24 (2 visits during each week), on an
outpatient basis, after overnight (8–10 h) fasting with
water ad libitum. During week 0 (baseline; 3 weeks after
the screening visit maximum), at the first visit, serum
and muscle samples were collected (see below and
Additional file 1), and a hyperinsulinemic-euglycemic
clamp was performed (see below). At the second visit
one week later, a standard meal test was performed (see
below), followed by proton magnetic resonance spectros-
copy (Magnetom Trio, Siemens, Erlangen, Germany) of
liver and skeletal muscle to measure lipid content as
described in Additional file 1. At the second visit, pa-
tients were randomized to (i) 5 g/day corn oil (Placebo),
(ii) 15 mg/day pioglitazone (Pio; Actos, Takeda), (iii)
5 g/day EPA + DHA concentrate (Omega-3; EPAX
1050TG, EPAX AS, containing about 15 % EPA, 40 %
DHA, wt/wt; i.e., ~2.8 g EPA + DHA), and (iv) the
combination of pioglitazone with EPAX 1050TG
(Pio& Omega-3). Randomization was performed using
a computer-based algorithm arranging experimental
units in blocks of four. The randomization code was
kept secret and revealed after the clean-file procedure
Fig. 1 Study design
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had been completed when all data had been filled in the
case report forms. Placebo and Omega-3 were adminis-
tered as gelatin-coated 1 g capsules. Thus, the study was
double blind for EPA +DHA and open-label for pioglita-
zone. During week 24, patients were handled similarly as
during week 0, except for also performing indirect calor-
imetry in conjunction with the clamp (see below).
Anthropometric measurements
Body weight (and height, data not shown) was mea-
sured using periodically calibrated scales accurate to
0.1 kg. Waist circumference was measured with a measur-
ing tape placed at the midpoint between the lowest rib
and the upper part of the iliac bone (results not shown).
Body mass index (BMI) was calculated using the Quetelet
formula (weight in kilograms divided by the square of the
body height). Blood pressure was measured after 5 min
in a seated position at rest, using a digital M6 Comfort
monitor (Omron, Kyoto, Japan). Three measurements
were taken 2 min apart. The first measurement was dis-
carded, and the mean of the remaining two measure-
ments was recorded.
Hyperinsulinemic-euglycemic clamp
A 3 h clamp (1 mU/kg.min−1), was conducted as
described previously [21]. A teflon cannula (Venflon;
Viggo, Helsingborg, Sweden) was inserted into an ante-
cubital vein for the infusion of all test substances. A sec-
ond cannula was inserted into a wrist vein for blood
sampling and the hand was placed in a heated (65 °C)
box to achieve venous blood arterialization. A stepwise
primed-continuous insulin infusion (1 mU/kg body
weight.min−1 of Actrapid HM; NovoNordisk, Copenhagen,
Denmark) was administrated to acutely raise and maintain
the plasma concentration of insulin at ~75 μU/ml.
Glycemia during the clamps was maintained at approx.
5.5 mmol/l by continuous infusion of 15 % glucose. Arter-
ialized blood glucose concentration was determined every
5–10 min as described in Other analytical methods (see
below) and the infusion rate was adjusted accordingly.
Mean plasma glucose concentrations were comparable
within the groups during clamps before and after 24 weeks.
The coefficients of variation of glycemia during the
studies were less than 5 %. Insulin sensitivity was esti-
mated as the glucose disposal rate (M), i.e. the amount
of glucose (mg/kg body weight.min−1) needed to main-
tain the concentration of glucose during the last 20 min
of the clamp.
Indirect calorimetry
At week 24, indirect calorimetry was conducted for
30 min (basal values in fasting state) just before and dur-
ing the last 30 min of the clamp, using an open-circuit
system (VMAX; SensorMedics, Anaheim, CA, USA).
Oxygen consumption (VO2; ml O2/min) and carbon di-
oxide production (VCO2; ml CO2/min) were recorded
every 1 min. To assess fuel partitioning, respiratory quo-
tient (RQ; RQ =VCO2/VO2) was estimated and substrate
utilization and resting energy expenditure (REE) were
calculated. Non-oxidative glucose disposal rate (GDR)
was calculated by subtracting the rate of glucose oxida-
tion from the total rate of glucose uptake during the last
20 min of the clamp [22].
Meal test
A meal test was performed as before [21]. After an
overnight fast, subjects received a standard breakfast
(baguette Crocodille Cheese Gourmet: 180 g, energy
452.8 kcal (1895.7 kJ)) of the following composition:
carbohydrates 49 g (45 % energy), proteins 18.5 g
(17 % energy), lipids 18.8 g (38 % energy), of which
saturated fatty acids 6.8 g, monounsaturated fatty acids
6.0 g, and polyunsaturated fatty acids 5.0 g. Serum con-
centrations of glucose, immunoreactive insulin, C-peptide,
non-esterified fatty acids (NEFA), and triacylglycerol were
measured at 0, 30, 60 and 120 min (see below in Other
analytical methods). Data were expressed as area under
the curve (AUC).
Content of selected fatty acids in serum phospholipids
Serum samples from fasted patients were analyzed
using shotgun lipidomics and mass spectrometry, and
a sum of concentrations of phospholipids containing
EPA and/or DHA divided by total concentration of all
phospholipids (Omega-3 PhL Index) was used as a
biomarker of EPA and DHA status. Briefly, 50 μl -aliquots
of serum were transferred into disposable borosilicate
glass tubes with 100 μl of methanol/butylated hydroxy-
toluene (1,000:1; v/v) containing internal standards for
quantification of lipid species: 17:0–17:0 phosphatidic
acid, phosphatidylethanolamine, phosphatidylcholine,
phosphatidylglycerol, phosphatidylserine, and phospha-
tidylinositol, respectively (75 nM final concentration).
Lipid extracts were prepared using a modified proced-
ure of Bligh and Dyer as previously described [23]. Each
lipid extract was diluted with dichloromethane/metha-
nol/isopropanol (1:2:4, v/v/v and 5 mM ammonium
acetate) prior to infusion into a mass spectrometer
(MS; QTRAP 5500, Sciex, USA; equipped with Turbo V
ESI) for the analysis of phospholipids. All the mass
spectra and tandem mass spectra were automatically
acquired using multiplexed precursor ion (PIS) and
neutral loss (NL) scans in positive and negative mode
[23]. Analyst 1.6.1/Lipidview 1.3 software was used to
identify molecular species and to determine amounts of
individual lipids based on internal standard concentra-
tions assuming comparable ionization of standards and
phospholipids. Sum formula annotation (e.g. PE 34:2)
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and acyl chain information coming from negative PIS
(e.g. PE 34:2 – PIS 18:2) was used to calculate the
additional acyl chain (e.g. PE 34:2 = 18:2 + 16:0). Only
combinations of the major fatty acids (carbon:double
bonds – 0:0, 12:0, 14:0, 14:1, 16:0, 16:1, 18:0, 18:1,
18:2, 18:3, 20:0, 20:1, 20:2, 20:3, 20:4, 20:5, 22:4, 22:5,
22:6) were used for further data processing. The con-
tent of linoleic acid (LA; 18:2 n-6) in serum phospho-
lipids was also determined.
Other analytical methods
Serum glucose levels were analyzed using the Beckman
Analyser glucose-oxidase method (Beckman Instruments,
Fullerton, CA, USA), plasma immunoreactive insulin and
C-peptide concentrations were determined using insulin
and C-peptide IRMA kits (Immunotech, Prague, Czech
Republic), HbA1c, was measured by HPLC (Tosoh, Tokyo,
Japan), lipid concentrations were assessed by enzymatic
methods (Roche, Basel, Switzerland) and HDL-cholesterol
was measured after double precipitation with dextran and
MgCl2 as described previously [24]. To assess oxida-
tive stress, the amount of lipid peroxidation was de-
termined as thiobarbituric acid reactive substances
(TBARS) by the reaction with thiobarbituric acid, the
whole blood level of reduced (GSH) and oxidized
(GSSG) glutathione was determined with glutathione
HPLC diagnostic kit (Chromsystems, Munich, Germany),
and the activity of superoxide dismutase (SOD) was ana-
lyzed using a superoxide dismutase assay kit (Cayman
Chemical, MI, USA). In fasting patients (Table 1), concen-
trations of serum cytokines were measured using ELISA
kits from Biovendor (Czech Republic; total adiponectin,
leptin), in the postabsortive state, various cytokines were
analyzed by microbead Luminex® assay (Luminex Corpor-
ation, Texas, United States; see Additional file 3). Serum
pioglitazone levels were estimated using mass spectrom-
etry (see above) [25].
Study endpoints
The primary endpoints were changes from baseline in
(i) insulin sensitivity (M; hyperinsulinemic-euglycemic
clamp) and (ii) fasting triacylglycerol levels at week
24. Secondary endpoints included the changes in fast-
ing glycemia and HbA1c, and postprandial change in
glucose, NEFA and triacylglycerol levels (meal test),
metabolic flexibility assessed by indirect calorimetry,
and inflammatory markers.
Statistical analysis
A power calculation indicated that 16 patients were
needed to detect a 7 % difference in M due to the inter-
vention with the probability 1 at the 0.05 level of signifi-
cance (assuming accuracy of measurement 5 %). All
values are presented as median and interquartile range
(IQR). Data from the baseline and the end of the study,
and the changes (Δ) between the baseline and the
end at week 24, were analyzed by the Kruskal-Wallis
one-way analysis of variance (ANOVA) using SigmaStat
3.5 (SSI, San Jose, CA, USA) and the statistical software R
version 3.1.0 (http://www.r-project.org). The Holm–
Bonferroni corrections for multiple comparisons were
used. Wilcoxon signed-rank test was used to analyze the
effect of intervention within each subgroup. Threshold of
significance was defined at a p value of ≤ 0.05. For the ana-
lysis of the dependence of the response (Δ value) of se-
lected variables on the corresponding change in Omega-3
PhL Index (Δ Omega-3 PhL Index), a linear regression
model with dummy variables that indicate a subgroup
Placebo, Pio, Omega-3, and Pio& Omega-3, respect-
ively, was used. Models were considered with interac-
tions since the effect of Δ Omega-3 PhL Index varies
by subgroups, so Δ Omega-3 PhL Index and subgroups
interact in affecting Δ value of selected variables.
Results
Basal characteristics
Of the 69 patients enrolled, data from 60 patients could
be used for the final evaluation (Fig. 1). Thus, 5 patients
withdrew owing to personal reasons; and after the inter-
vention started, 1 patient was excluded due to failure to
adhere to the study protocol. Based on serum pioglita-
zone measurements (not shown), 3 patients were ex-
cluded due to detection of pioglitazone already at the
baseline, while the pioglitazone levels assessed at week
24 confirmed adherence to the study protocol in the Pio
and Pio& Omega-3 subgroups.
No significant differences were observed between the
subgroups in basic anthropometric and biochemical
characteristics measured in the fasting state during the
study (Table 1). In the subgroup analysis by the effect of
the 24-week-intervention (see Δ-values in Table 1), both
Pio and Pio& Omega-3 increased body weight and BMI
compared with Placebo or Omega-3 (except for Placebo
vs. Pio in the case of body weight; p = 0.10). Triacylglyc-
erol, NEFA and total cholesterol in serum, blood lipo-
proteins including HDL cholesterol and LDL cholesterol,
and markers of oxidative stress in serum including SOD
activity, TBARS and GSSG/GSH ratio were not signifi-
cantly affected by any of the interventions (Table 1).
Magnetic resonance spectroscopy did not show any
significant effect of the interventions on the ectopic
lipid content (see Additional file 1). Leptin levels were
increased in Pio compared with the other subgroups
(p = 0.02). At week 24, adiponectin levels were higher in
Pio and Pio& Omega-3 than in Placebo subgroup, reflect-
ing ~1.6-fold fold stimulatory effect in the median con-
centration in both Pio and Pio& Omega-3 (p < 0.0001).
Adiponectin levels in the Omega-3 subgroup were higher,
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Table 1 Basic anthropometric and biochemical characteristics of patients at baseline and after the interventions. The significance
threshold for adjusted p-values using the Holm-Bonferroni correction is 0.05
Placebo Pio Omega-3 Pio& Omega-3
Age (y) 62.0 (58.0, 65.0) 62.0 (60.0, 65.0) 59.5 (55.8, 63.8) 60.5 (55.3, 65.5)
Systolic blood pressure (mmHg)
Baseline 138 (129, 149) 142 (136, 151) 146 (135, 153) 139 (131, 145)
Week 24 140 (131, 146) 142 (134, 148) 137 (131, 150) 136 (127, 148)
Δ 2 (−3, 7) 1 (−5, 3) −5 (−8, 2) −1 (−8, 1)
Δ (%) 1 (−2, 5) 1 (−3, 2) −3 (−5, 1) 0 (−6, 1)
Diastolic blood pressure (mmHg)
Baseline 82 (77, 93) 85 (79, 91) 90 (83, 92) 81 (69, 94)
Week 24 85 (70, 90) 82 (73, 89) 86 (75, 90) 82 (76, 92)
Δ 1 (−6, 6) −1 (−9, 2) 0 (−5, 2) 1 (−7, 5)
Δ (%) 1 (−8, 7) −1 (−8, 2) 0 (−5, 3) 1 (−8, 7)
Body weight (kg)
Baseline 87.0 (81.2, 103.0) 94.0 (85.0, 102.0) 98.8 (95.2, 110.5) 94.0 (79.5, 107.0)
Week 24 84.0 (79.0, 103.0) 95.0 (88.0, 103.0) 97.5 (91.5, 108.3) 95.5 (83.0, 111.5)
Δ −1.0 (−2.0, 0.0) 1.0 (0.0, 2.8)c −1.5 (−2.6, 1.0) 2.0 (1.0, 3.0)a, c
Δ (%) −1.2 (−2.4, 0.0) 1.3 (0.0, 2.3)c −1.3 (−2.7, 0.8) 1.9 (1.0, 4.2)a, c
BMI (kg/m2)
Baseline 30.9 (27.7, 33.5) 32.0 (29.6, 35.4) 34.0 (29.2, 37.5) 31.4 (27.9, 39.8)
Week 24 30.5 (27.4, 32.6) 32.4 (30.2, 36.6) 33.1 (28.7, 37.9) 32.0 (28.7, 40.6)
Δ −0.4 (−0.8, 0.0) 0.4 (0.0, 0.9)a, c −0.5 (−1.0, 0.3) 0.7 (0.4, 1.2)a, c
Δ (%) −1.4 (−2.5, 0.0) 1.3 (0.0, 2.3)a, c −1.3 (−2.7, 0.8) 2.0 (1.1, 4.2)a, c
Triacylglycerol (mmol/l)
Baseline 1.45 (1.23, 1.76) 1.70 (1.17, 2.41) 2.17 (1.50, 2.76) 1.71 (1.32, 2.21)
Week 24 1.41 (1.10, 2.28) 1.89 (1.24, 2.36) 1.67 (1.53, 2.31) 1.52 (1.06, 2.05)
Δ 0.21 (−0.13, 0.48) 0.13 (−0.11, 0.66) −0.48 (−0.73, 0.36) −0.14 (−0.58, −0.02)
Δ (%) 10.1 (−10.6, 31.3) 4.9 (−13.0, 52.4) −18.2 (−23.8, 20.2) −12.2 (−24.0, −1.1)
NEFA (mmol/l)
Baseline 0.73 (0.64, 0.79) 0.82 (0.64, 1.04) 0.65 (0.54, 0.91) 0.69 (0.53, 0.74)
Week 24 0.65 (0.51, 0.87) 0.51 (0.37, 0.79) 0.60 (0.47, 0.85) 0.53 (0.31, 0.70)
Δ 0.21 (−0.13, 0.48) 0.13 (−0.11, 0.66) −0.48 (−0.73, 0.36) −0.14 (−0.58, −0.02)
Δ (%) −11.0 (−40.7, 13.0) −43.2 (−50.0, −15.4) −16.0 (−47.6, 25.7) −9.4 (−43.0, 18.7)
Cholesterol total (mmol/l)
Baseline 4.60 (4.00, 5.60) 4.54 (3.70, 5.50) 4.70 (4.49, 5.37) 5.25 (4.78, 5.95)
Week 24 4.40 (3.53, 5.32) 4.47 (3.61, 5.06) 4.62 (4.40, 5.12) 4.56 (4.32, 5.45)
Δ −0.47 (−0.62, −0.20) −0.07 (−0.40, 0.74) −0.13 (−0.62, 0.21) −0.23 (−0.87, −0.04)
Δ (%) −9.8 (−15.9, −4.3) −2.0 (−7.8, 13.5) −2.9 (−12.9, 4.5) −4.7 (−16.4, −0.7)
HDL cholesterol (mmol/l)
Baseline 1.09 (1.00, 1.29) 1.02 (0.90, 1.16) 1.17 (0.94, 1.28) 1.18 (1.03, 1.28)
Week 24 1.04 (0.79, 1.17) 1.07 (0.96, 1.18) 1.04 (0.91, 1.25) 1.24 (1.10, 1.58)
Δ −0.05 (−0.14, −0.04) 0.07 (−0.05, 0.12) −0.04 (−0.14, 0.05) 0.12 (0.00, 0.22)
Δ (%) −4.8 (−10.9, −2.2) 6.2 (−6.5, 8.8) −2.8 (−14.4, 4.4) 10.5 (0.9, 19.2)
LDL cholesterol (mmol/l)
Baseline 2.45 (2.00, 3.29) 2.21 (1.70, 2.70) 2.70 (2.28, 3.00) 2.75 (2.37, 3.32)
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reflecting 1.2-fold increase in the median in this subgroup
(p < 0.001) but were unchanged in the Placebo subgroup
(Table 1).
Omega-3 PhL Index was similar in all subgroups at
the baseline, while at week 24 it was not affected by ei-
ther Placebo or Pio, but increased to a similar extent
(1.6–1.7-fold; p < 0.0001 and p = 0.0001, respectively) in
response to both Omega-3 and Pio& Omega-3 (Table 1).
As observed before [26], Omega-3 PhL Index differed
between individuals, showing up to ~3-fold differences
when all 60 patients were compared at the baseline
(Fig. 2 a-d). In the EPA +DHA supplemented subgroups
(Omega-3 or Pio& Omega-3) a maximum ~2.2-fold dif-
ference in the median Omega-3 PhL Index was observed
between individuals at the end of the intervention
(Table 1). The variable increase in the Omega-3 PhL
Index in response to EPA +DHA supplementation was
independent of the pre-intervention value (Fig. 2 c, d).
Table 1 Basic anthropometric and biochemical characteristics of patients at baseline and after the interventions. The significance
threshold for adjusted p-values using the Holm-Bonferroni correction is 0.05 (Continued)
Week 24 2.60 (1.90, 3.02) 2.60 (1.86, 2.94) 2.81 (2.56, 3.24) 3.03 (2.33, 3.53)
Δ −0.09 (−0.20, 0.00) 0.13 (−0.03, 0.41) 0.16 (−0.17, 0.70) 0.30 (−0.17, 0.65)
Δ (%) −4.4 (−5.5, 0.0) 7.6 (−1.2, 16.6) 6.8 (−5.6, 27.9) 10.6 (−7.7, 20.2)
SOD (U/ml)
Baseline 1.40 (0.76, 1.89) 1.44 (0.75, 2.15) 0.90 (0.58, 1.38) 1.16 (0.78, 1.76)
Week 24 1.22 (0.99, 1.76) 1.11 (0.86, 1.99) 0.90 (0.70, 1.35) 0.88 (0.48, 1.25)
Δ 0.05 (−0.67, 0.29) 0.21 (−0.33, 0.46) 0.07 (−0.25, 0.46) −0.23 (−0.68, 0.23)
Δ (%) 2.2 (−33.4, 38.5) 24.3 (−23.0, 43.1) 8.9 (−22.0, 46.1) −18.0 (−49.5, 34.8)
TBARS (mmol/l)
Baseline 1.71 (1.33, 2.04) 1.40 (1.16, 2.14) 1.46 (1.35, 2.29) 1.64 (1.26, 2.10)
Week 24 1.42 (1.00, 1.64) 1.36 (0.97, 1.75) 1.12 (0.76, 1.43) 1.28 (0.97, 1.47)
Δ −0.23 (−0.76, 0.28) −0.10 (−0.42, 0.05) −0.59 (−0.93, 0.12) −0.20 (−0.78, 0.09)
Δ (%) −17.5 (−34.5, 25.8) −6.7 (−22.6, 3.2) −43.0 (−56.4, 11.9) −10.8 (−43.9, 11.2)
Ratio GSSG/GSH
Baseline 0.17 (0.12, 0.20) 0.14 (0.11, 0.17) 0.11 (0.09, 0.15) 0.11 (0.08, 0.16)
Week 24 0.11 (0.11, 0.15) 0.13 (0.10, 0.14) 0.12 (0.08, 0.18) 0.14 (0.11, 0.20)
Δ −0.04 (−0.09, 0.02) 0.00 (−0.08, 0.03) 0.00 (−0.02, 0.03) 0.01 (−0.02, 0.06)
Δ (%) −20.9 (−47.5, 19.9) −3.4(−48.1, 67.3) 2.1 (−19.2, 38.7) 9.0 (−12.7, 53.2)
Leptin (ng/ml)
Baseline 13.2 (10.6, 17.2) 12.6 (10.0, 26.1) 12.7 (7.0, 23.9) 21.7 (9.7, 30.4)
Week 24 14.4 (7.8, 15.8) 13.0 (9.2, 33.3) 11.3 (7.9, 21.7) 21.0 (8.5, 41.3)
Δ −0.8 (−1.8, 0.6) 2.4 (0.5, 3.0) −1.1 (−2.9, 1.0) −0.3 (−1.1, 0.5)
Δ (%) −3.2 (−14.5, 6.8) 10.3 (1.4, 29.4) −9.9 (−20.9, 12.2) −1.9 (−3.8, 3.5)
Adiponectin (μg/ml)
Baseline 6.3 (5.6, 7.3) 5.7 (4.6, 6.9) 5.3 (4.7, 5.9) 5.6 (4.8, 6.4)
Week 24 6.3 (4.9, 9.0) 9.1 (7.4, 12.8)a, c 6.4 (5.7, 7.2) 8.9 (7.5, 9.9)a, c
Δ 0.4 (0.0, 1.0) 3.5 (2.6, 5.0)a, c 0.9 (0.6, 1.2) 3.7 (2.6, 4.8)a, c
Δ (%) 9.4 (−0.2, 27.4) 60.0 (45.4, 73.4)a, c 15.8 (9.0, 26.9) 64.7 (44.6, 91.8)a, c
Omega-3 PhL Index
Baseline 4.9 (4.3, 5.8) 5.2 (4.4, 5.8) 4.9 (4.6, 5.5) 5.3 (4.1, 5.7)
Week 24 4.4 (4.1, 4.8) 4.5 (4.2, 5.2) 8.2 (7.1, 8.9)a, b 8.3 (7.4, 9.2)a, b
Δ −0.1 (−0.5, 0.2) −0.3 (−0.7, 0.2) 2.8 (2.1, 4.4)a, b 3.4 (2.5, 3.6)a, b
Δ (%) −2.6 (−10.5, 4.6) −5.2 (−13.9, 2.7) 60.8 (43.9, 88.5)a, b 62.8 (41.4, 99.9)a, b
Data represent a median and interquartile range (Q1, Q3). Various parameters were analyzed in overnight (8–10-h) fasting patients at baseline and at week 24 of
the respective interventions. Δ, a difference between week 24 and baseline values; Δ (%), a difference between week 24 and baseline values in % of the baseline
value; BW, body weight; BMI, body mass index, NEFA, non-esterified fatty acids; SOD, superoxide dismutase; TBARS, thiobarbituric acid reactive substances; GSSH,
oxidized glutathione; GSH, reduced glutathione. a, b, cSignificant differences compared with Placebo, Pio, and Omega-3, respectively
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In contrast with the Omega-3 PhL Index (i.e., the EPA
and DHA in serum phospolipids), LA content in phos-
pholipids was not affected by any intervention and no
differences in LA content between the subgroups of pa-
tients were found, either before or after the intervention
(see Additional file 2).
Glucose metabolism
No differences between Placebo, Pio and Pio& Omega-3
subgroups were observed in the markers of acute and
long-term glycemic control, i.e., fasting blood glucose
and serum HbA1c level, respectively, either at baseline,
or at week 24 (Table 2). In response to Omega-3, both
parameters increased by ~1.2-fold (fasting blood glucose,
p = 0.02; HbA1c, p = 0.01) resulting in a significant effect
of Omega-3 (see Δ-values in Table 2) and indicating a
marginal deterioration of glycemic control. Glucose dis-
posal rate, assessed using hyperinsulinemic-euglycemic
clamp (M value), is a measure of insulin sensitivity.
While it was similar in all the subgroups at baseline, M
increased (p = 0.04) in Pio& Omega-3 subgroup during
the intervention and at week 24, it was higher in the
Pio& Omega-3 compared with the Omega-3 sub-
group. In the subgroup analysis by the effect of the
intervention (see Δ-values in Table 2), the effect of
Pio (p = 0.12) and Pio& Omega-3 (p = 0.12) tended to
be different from that of Omega-3. Thus, regarding
the effects on insulin sensitivity, Omega-3 exerted a
neutral effect compared with Placebo, while the re-
sults collectively document a marginal improvement
by the Pio& Omega-3 intervention.
Energy metabolism and metabolic flexibility
At week 24, indirect calorimetry was performed in con-
junction with the hyperinsulinemic-euglycemic clamp.
None of the measured parameters, namely REE, RQ,
carbohydrate oxidation and fat oxidation were signifi-
cantly different between the subgroups before or during
the clamp. Non-oxidative GDR, assessed during the
clamp, was also similar in all subgroups (Table 3).
Next, we attempted to detect possible differences in
metabolic flexibility between the subgroups at week 24.
We focused on the increase in RQ during the clamp, as
a common way for assessment of metabolic flexibility to
Fig. 2 Omega-3 PhL Index in individual patients. Analysis was performed at baseline (white bars) and at week 24 (black bars) in Placebo (a) Pio
(b) Omega-3 (c) and Pio& Omega-3 (d) subgroups. Case numbers are indicated
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carbohydrates, which is usually impaired in insulin-
resistant individuals [27]. No significant differences in
the increase in median RQ between the subgroups were
observed (Table 3). Therefore, a robust approach based
on the evaluation of percent relative cumulative frequency
(PRCF) curves of RQ values was used while pooling all
RQ values from all the patients within subgroups. This
was done for both fasting and clamp periods (Fig. 3).
Provided that the PRCF curve represents normally distrib-
uted data, the value of EC50 of PRCF (50
th percentile)
Table 2 Glucose homeostasis and insulin sensitivity at baseline and after the intervention. The significance threshold for adjusted
p-values using the Holm-Bonferroni correction is 0.05
Placebo Pio Omega-3 Pio& Omega-3
HbA1c (IFCC, mmol/mol)
Baseline 52 (48, 56) 52 (47, 54) 50 (47, 55) 49 (44, 53)
Week 24 49 (48, 51) 49 (46, 55) 58 (51, 73) 48 (46, 53)
Δ 0 (−5, 1) 0 (−5, 1) 7 (1, 13)a, b 0 (−3, 2)
Δ (%) 0.0 (−8.9, 2.1) 0.0 (−7.6, 1.9) 14.7 (2.6, 22.1)a, b 0.0 (−6.2, 3.9)
Fasting blood glucose (mmol/l)
Baseline 7.31 (6.40, 8.27) 7.48 (7.15, 8.47) 7.67 (6.53, 8.87) 7.10 (6.51, 8.18)
Week 24 7.26 (5.99, 8.17) 7.39 (6.79, 8.00) 9.10 (7.34, 10.50) 7.22 (6.59, 8.44)
Δ −0.10 (−1.32, 0.80) −0.25 (−0.78, 0.01) 1.07 (0.18, 2.02)b 0.05 (−0.51, 0.47)
Δ (%) −1.2 (−18.1, 12.4) −3.7 (−8.4, 0.1) 17.0 (1.6, 25.2)b 0.8 (−5.6, 7.4)
M (mg/kg.min−1)
Baseline 3.42 (2.38, 3.97) 2.51 (2.12, 4.10) 2.66 (2.15, 3.34) 3.21 (2.52, 3.68)
Week 24 2.79 (1.89, 3.09) 2.93 (2.69, 4.47) 2.33 (1.18, 3.41) 3.55 (3.08, 4.34)c
Δ −0.60 (−1.24, 0.60) 0.29 (−0.34, 1.30) −0.58 (−1.25, −0.13) 0.53 (−0.20, 0.92)
Δ (%) −17.1 (−38.1, 17.2) 12.0 (−13.0, 52.7) −21.2 (−41.0, 1.9) 14.6 (−6.2, 40.3)
Data represent a median and interquartile range (Q1, Q3). Glycemia and plasma HbA1c levels were measured in overnight (8–10-h) fasting patients, while glucose
disposal rate (M) was evaluated using hyperinsulinemic-euglycemic clamp at baseline and at week 24. Δ, a difference between week 24 and baseline values, Δ (%),
a difference between week 24 and baseline values in % of the baseline value. a, b, cSignificant differences compared with Placebo, Pio, and Omega-3, respectively
Table 3 Energy metabolism and substrate utilization after the intervention. The significance threshold for adjusted p-values using
the Holm-Bonferroni correction is 0.05
Placebo Pio Omega-3 Pio& Omega-3
REE (kcal/day) 1585 (1410, 2157) 1611 (1534, 1816) 1780 (1653, 2000) 1566 (1503, 1733)
RQ
Fasting state 0.80 (0.77, 0.83) 0.79 (0.77, 0.85) 0.77 (0.74, 0.83) 0.80 (0.76, 0.83)
During clamp 0.85 (0.81, 0.91) 0.87 (0.83, 0.91) 0.86 (0.83, 0.87) 0.89 (0.84, 0.91)
Diff C-F 0.07 (0.02, 0.08) 0.06 (0.03, 0.09) 0.08 (0.02, 0.11) 0.07 (0.06, 0.10)
Carbohydrate oxidation (mg/kg.min−1)
Fasting state 0.77 (0.42, 1.18) 0.78 (0.47, 1.39) 0.44 (0.17, 0.92) 0.66 (0.43, 1.27)
During clamp 1.09 (0.65, 1.99) 1.15 (0.88, 1.51) 1.17 (1.02, 1.32) 1.50 (1.17, 1.73)
Diff C-F 0.59 (0.28, 0.79) 0.51 (0.00, 0.71) 0.90 (0.29, 1.13) 0.77 (0.41, 0.82)
Fat oxidation (mg/kg.min−1)
Fasting state 0.80 (0.52, 0.88) 0.70 (0.31, 0.80) 0.91 (0.50, 1.01) 0.61 (0.48, 0.89)
During clamp 0.43 (0.29, 0.73) 0.34 (0.24, 0.52) 0.46 (0.34, 0.61) 0.32 (0.13, 0.47)
Diff C-F −0.38 (−0.43, −0.1) −0.20 (−0.39, −0.08) −0.31 (−0.54, −0.10) −0.35 (−0.40, −0.24)
Non-oxidative GDR (mg/kg.min-1)
1.47 (0.87, 2.00) 1.80 (1.28, 2.51) 0.60 (0.05, 1.74) 2.32 (1.46, 2.81)
Data represent a median and interquartile range (Q1, Q3). Data were obtained using indirect calorimetry performed in conjunction with hyperinsulinemic-
euglycemic clamp at week 24 (see Table 2). Differences between parameters measured during the clamp and fasting state are also shown (Diff C-F). REE, resting
energy expenditure; RQ, respiratory quotient; GDR, glucose disposal rate (indirect calorimetry). For evaluation of the effect of respective interventions on RQ (meta-
bolic flexibility), see also Fig. 3. Non-oxidative glucose GDR was calculated as described in Methods. No significant differences between subgroups were found
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corresponds to a mean RQ value, while these curves
also allow to identify differences that may exist at either
lower or upper levels of RQ range [28]. During the
clamp, PRCF curves within each subgroup shifted to
the right (i.e., towards glucose oxidation), documenting
various degrees of metabolic flexibility to glucose. Com-
pared to Placebo, metabolic flexibility was improved
by all interventions in the following order of effect:
Pio < Omega-3 < Pio& Omega-3 (see the PRCF curve
shifts in the legend to Fig. 3).
Postprandial metabolism
A meal test was performed at baseline and at week 24,
allowing for assessment of the effects on postprandial
metabolism of both glucose and lipids, and of the insulin
response to a carbohydrate load. Transient increases in
serum glucose, C-peptide, NEFA and triacylglycerol (and
insulin; not shown) levels triggered by a standard break-
fast were followed during 120 min. Data were expressed
as AUC (Fig. 4). At baseline, no significant differences
between the subgroups were observed; at week 24, Pio&
Omega-3 subgroup showed faster metabolism of triacyl-
glycerol (lower AUC) compared with both Placebo and
Omega-3 (p = 0.04; not shown). In the subgroup analysis
by the effect of the intervention, several significant re-
sults were obtained. Thus, the difference between AUC
at week 24 and baseline (ΔAUC) for glucose was higher
in Omega-3 compared with the other subgroups (Fig. 4a;
except for Omega-3 vs. Pio& Omega-3, p = 0.06), sug-
gesting a deterioration of glucose metabolism. In the
case of C-peptide (and insulin; not shown), no signifi-
cant differences between the interventions were found
(Fig. 4b). Postprandial metabolism of NEFA was acceler-
ated in response to Pio& Omega-3, as documented by
the lower ΔAUC in this subgroup compared with both
Placebo and Omega-3 (Fig. 4c). Regarding the metabol-
ism of triacylglycerols (Fig. 4d), ΔAUC was similar in the
Placebo, Pio and Omega-3 subgroup, while it was de-
creased in response to Pio& Omega-3.
Previous studies showed an anti-inflammatory effect
of EPA + DHA at the level of some plasma cytokines
in the postprandial state [29]. Therefore, various anti-
inflammatory (IL-1RA and IL-10) and pro-inflammatory
cytokines (MCP-1, CRP, TNF-α and IL-6), as well as
proteins involved in cell adhesion (sVCAM-1, sICAM-1,
sE-selectin, sP-selectin, sPECAM-1) and neovasculariza-
tion (sCD105) were evaluated in serum samples collected
at 120 min of the test, both at baseline and week 24.
Except for sP-selectin, no significant effects of the in-
terventions were observed (see Additional file 3).
Discussion
We show here that a 6-month-combined intervention
using a relatively low dose of pioglitazone and a dose of
EPA +DHA, which is within the range that is approved
for treatment of hypertriacylglycerolemia [13], exerts
additive beneficial effects on metabolism of both NEFA
and triacylglycerols in T2D patients (Fig. 4). All the pa-
tients were already receiving metformin therapy and well
compensated regarding glycemic control at the baseline,
Fig. 3 Metabolic flexibility after the interventions. RQ data from indirect calorimetry at week 24 (see Table 3) were used to construct PRCF curves,
each of which represents data (~400) pooled from all patients in the given subgroup either in fasting state (dashed lines) or during clamp
(solid lines). RQ values corresponding to EC50 (50
th percentile value) on each of the curves were obtained and the difference between this RQ
value assessed during the clamp and fasting, respectively, was used as a marker of metabolic flexibility to glucose (PRCF curve shift; Placebo,
0.04; Pio, 0.06; Omega-3, 0.06; Pio& Omega-3, 0.07)
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and most of them were obese, thus representing a typical
population of patients treated for T2D.
In spite of the triacylglycerol-lowering effect of EPA +
DHA, shown in many studies, including those in pa-
tients with T2D, as well as the hypolipidemic effects of
thiazolidinediones (see Background), fasting serum triac-
ylglycerol levels were not significantly affected by any of
the studied interventions. It is likely that the background
metformin therapy, which was shown to improve dyslip-
idemia in patients with T2D [30], could mask the effect
of the tested interventions. This is also consistent with
the notion that most of the studies demonstrating the
triacylglycerol-lowering effect of EPA +DHA in the pa-
tients with T2D were performed before the beginning of
the metformin era as well as the use of thiazolidinedione
therapy of these patients. Moreover, metformin could
also mask the additive triacylglycerol-lowering effects of
EPA + DHA in T2D dyslipidemic patients under statin
therapy, which was observed before [31] but not in
our study (not shown). Nevertheless, the additive
improvement in metabolism of both NEFA and triac-
ylglycerols by the combined intervention found using
the meal test in this study (Fig. 4) suggests that in-
creased intake of EPA + DHA could reduce the car-
diovascular risk even in T2D patients treated with
metformin. This complex effect of the combined
intervention is of clinical relevance because increased
postprandial triacylglycerolemia represents an inde-
pendent risk factor of cardiovascular disease in T2D
patients [10, 17]. The mechanisms behind the effect
of the combined intervention on metabolism of NEFA
and triacylglycerols require clarification. It is likely
that PPARα-mediated catabolism of fatty acids [12]
and/or their trapping in adipose tissue, i.e., the bio-
chemical activities that are possibly altered in the pa-
tients (reviewed in [32]), could contribute to the
NEFA-lowering effect. Regarding the beneficial effect
on metabolism of triacyglycerols, depression of the
rate of VLDL-triacyglycerol secretion from the liver
should be considered [7, 33].
Fig. 4 The effects of interventions on postprandial metabolism of selected metabolites and insulin response. A meal test was performed in
overnight fasted patients at baseline and at week 24. Transient postprandial increases in serum concentrations of various analytes were evaluated
during 120 min following a standard breakfast. The difference between total AUC for each analyte measured at week 24 and baseline (ΔAUC) is
shown for glucose (a) C-peptide (b) NEFA (c) and triacylglycerol TG; (d). Plots represent 10th, 25th, 50th (median), 75th, and 90th percentiles.
Significant differences (Kruskal-Wallis test) between the subgroups are indicated
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That all the patients were well-controlled under
metformin therapy could also affect other results of
the study. First, it could explain why no effect on
proteins linked to inflammation (anti – inflammatory
cytokines, namely IL-1RA, IL-10, and pro-inflammatory
cytokines, namely MCP-1, CRP, TNF-α, IL-6) was ob-
served (Additional file 3), since metformin is known to
exert anti-inflammatory action [3]. Indeed cytokine and
adhesion molecule concentrations (cVCAM-1, sICAM-1,
sE-selectin, sPECAM-1) were similar to those reported for
healthy male subjects of different ages [34]. Importantly,
no deleterious effects of any of the interventions on the
markers of oxidative stress (SOD, TBARS, ratio GSSG/
GSH) were observed (Table 1), possibly, due to the anti-
oxidant effect of metformin [4]. Similarly, also insulin
secretion remained unaffected by the interventions
(see Results, Postprandial metabolism).
Second, only limited additional benefits of pioglitazone
and/or Omega-3 may be expected in metformin treated
T2D patients. In fact, Omega-3 alone marginally im-
paired markers of glycemic control (HbA1c levels and
fasting glycemia; Table 2) and glucose metabolism in
the meal test (Fig. 4), but did not diminish insulin
sensitivity (M) evaluated using a hyperinsulinemic-
euglycemic clamp (Table 2). These results are com-
patible with a model in which EPA + DHA per se do
not deteriorate glucose utilization when glucose repre-
sents the main energy fuel (Fig. 5, Clamp). However, when
the supply of both carbohydrates and lipids is increased
(e.g., during the meal test; Fig. 5, Fed), or when fatty acids
liberated from adipose tissue represent the main en-
ergy fuel (Fig. 5, Fasting), glucose utilization is inhib-
ited by multiple mechanisms involved in the Randle
cycle (reviewed in [35]) reflecting the PPARα-mediated
stimulation of fatty acid oxidation by EPA +DHA [12].
This would lead to the observed subtle deterioration of
glucose metabolism by Omega-3. Metabolic changes in
skeletal muscle, the main site of glucose utilization,
Fig. 5 The effects of omega-3 fatty acids on glucose metabolism in insulin-sensitive tissues depend on energy fuels. When glucose serves as the
major energy substrate (Clamp), glucose utilization is only marginally affected. With increased postprandial intake of both carbohydrates and lipids
(Fed/postprandial), or when fatty acids (FA) serve as the major fuel (Fasting), β-oxidation is stimulated by EPA + DHA via PPARα-signaling
[12], which results in reduced glucose utilization (red dashed lines) by several mechanisms involving the Randle cycle (55). Inhibition of
glucose oxidation at the level of pyruvate dehydrogenase (PDH) by acetyl-CoA (a) leads also to rerouting of pyruvate to anaplerosis (muscle) and/or
gluconeogenesis (liver); citrate accumulation in the cytosol results in inhibition of glucose uptake (b) and inhibition of glycolysis (c) at the level of
hexokinase (HK)
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probably play a major role. That fasted glycemia is se-
lectively increased by Omega-3 (Table 2) could also
reflect increased hepatic gluconeogenesis stimulated
in face of enhanced fatty acid oxidation [36]. Both de-
creased postprandial metabolism of glucose (Fig. 4)
and elevated glycemia in fasted state could contribute
to raised HbA1c levels in the Omega-3 subgroup
(Table 2). Thus, our results also help to clarify some
controversies regarding the effects of EPA + DHA on
glucose homeostasis in T2D patients (see Background).
The negative effects of Omega-3 on glycemic con-
trol and glucose metabolism were prevented by Pio.
Insulin sensitivity was increased by Pio&Omega-3,
and tended to be improved by Pio compared with
Omega-3 (Table 2), which is also in agreement with
the induction of adiponectin by both Pio& Omega-3
and Pio (Table 1). These results were consistent with
changes in metabolic flexibility to glucose evaluated
using indirect calorimetry during the hyperinsulinemic-
euglycemic clamp at week 24 (Fig. 3), since this parameter
closely reflects whole-body glucose uptake [27]. Thus,
all the interventions, and especially Pio& Omega-3,
increased metabolic flexibility. These results are con-
sistent with the above model and also with our previ-
ous study showing additive improvement in metabolic
flexibility [20] and insulin sensitivity [7] by combined
interventions using EPA + DHA and thiazolidinediones
in dietary obese mice. In both the animal experiments
and the present clinical trial, the robust PRCF analysis
of RQ was used. This approach, which revealed here
subtle differences in metabolic flexibility, has not been
applied in humans before.
Few studies were conducted to characterize possible
modulation of metabolic flexibility by EPA + DHA in
T2D patients, and very little is known about the ef-
fects of combined interventions using EPA + DHA
and pharmaceuticals. It has been shown that EPA +
DHA administered as a 4-h lipid infusion resulted in
a marginal improvement of metabolic flexibility with-
out affecting insulin sensitivity [37]. Over a 9-week-
period, dietary EPA + DHA exerted a transient im-
provement of glucose utilization followed by a shift
from glucose to lipid catabolism, but the effect on
metabolic flexibility is difficult to assess from these
data since a relatively large volume (20 ml) of crude
fish oil containing different lipid fractions besides
EPA + DHA was used [38]. Thus, our study is unique
regarding the use of a complex methodological ap-
proach including the indirect calorimetry, clamp as
well as a meal test, which allowed us to demonstrate
the additive improvements in metabolic flexibility to
glucose, and namely in the postprandial lipid metab-
olism, by pioglitazone in combination with highly
purified EPA + DHA.
Evaluation of serum levels of both pioglitazone and
EPA +DHA increased the power of the study by control-
ling the adherence to the therapy, and enabled a more
detailed analysis of the measured parameters relative to
the changes in Omega-3 PhL Index. However, only weak
correlations (p < 0.1) were detected when an increase in
HbA1c levels or a decrease in NEFA levels was examined
(see Additional file 4). Further studies are needed to
analyze the mechanisms behind the metabolic effects of
interventions observed in our study, including the evalu-
ation of changes in muscle glycogen content during the
clamp. In this context, muscle glycogen was measured
only in the fasting state and no differences between the
subgroups were found (Additional file 1).
In spite of the fact that pioglitazone is a well-established
pharmaceutical with lasting insulin-sensitizing effects, and
despite its other beneficial effects in patients with T2D, its
clinical use has declined recently due to the risk of the
side-effects (see Background). Importantly, at least some
of these concerns have been disproved recently. Namely,
it has been demonstrated that the cumulative use of pio-
glitazone or rosiglitazone was not associated with the inci-
dence of bladder cancer [39]. The results of our study
document beneficial effects of a relatively low dose of pio-
glitazone on lipid metabolism when pioglitazone was used
as part of the combined intervention with n-3 fatty acids.
This observation is relevant for reducing the risk of the
side-effects of pioglitazone under clinical settings.
Conclusions
In overweight/obese T2D patients on stable metformin
therapy, and in spite of the modest negative effect of
Omega-3 on glycemic control and postprandial glucose
metabolism, no adverse effect on insulin sensitivity was
observed. In response to the combined intervention
using Pio& Omega-3, the negative effect of Omega-3 on
glucose metabolism was avoided, insulin sensitivity in-
creased, and lipid metabolism was additively improved.
Thus, typical T2D patients may be advised to increase
their EPA + DHA intake, either in the form of dietary
supplements or sea food and fish, in order to increase
the efficacy of pharmacotherapies and to prevent dis-
eases linked to inflammation as well as cardiovascular
disease, providing that glycemic control is closely moni-
tored. EPA +DHA are likely to bring benefits on cardio-
vascular health of diabetic patients.
Additional files
Additional file 1: Liver and muscle lipid content before and after
the intervention and muscle glycogen content after the
intervention. (DOCX 44 kb)
Additional file 2: The content of linoleic acid (LA) in serum
phospholipids. (DOCX 94 kb)
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Additional file 3: Serum levels of inflammatory markers in the
postprandial state. (DOCX 39 kb)
Additional file 4: Correlations between changes in Omega-3 PhL
Index and changes in selected variables in response to interven-
tions. (DOCX 22909 kb)
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GSSG: oxidized glutathione; HbA1c: hemoglobin A1c; IL: interleukin;
IQR: interquartile range; LA: linoleic acid (18:2 n-6); M: glucose disposal
rate (hyperinsulinemic-euglycemic clamp); NEFA: non-esterified fatty
acids; Omega-3: EPA + DHA concentrate (5 g/day) supplementation;
Omega-3 PhL Index: relative concentration of EPA + DHA in plasma
phospholipids; Pio: pioglitazone (15 mg/day) intervention; Pio& Omega-
3: pioglitazone (15 mg/day) intervention combined with EPA + DHA
concentrate (5 g/day) supplementation; PPAR: peroxisome proliferator-
activated receptor; PRCF: percent relative cumulative frequency; REE: resting
energy expenditure; RQ: respiratory quotient; SOD: superoxide dismutase;
T2D: type 2 diabetes; TBARS: thiobarbituric acid reactive substances;
VCO2: carbon dioxide production; VO2: oxygen consumption.
Competing interests
The authors declare that they have no competing interests associated with
this study.
Authors’ contributions
MB, PCC, JK Sr., TP designed the study and wrote the manuscript. JV, JK Jr.
and TP recruited the patients and acquired the clinical data. PJ, OK, OH, HM,
LK, OO, VS, JT, MH, AS, PF, KB, MR, JO, GSC, and JJ were involved in the
acquisition and analysis of the laboratory data. AG and EF carried out the
statistical analyses and interpretation of the data. All authors had full access
to data and approved the manuscript for publication. JK Sr. and TP wrote
the grant application and are the guarantors.
Acknowledgements
This work was supported by the grant from the Ministry of Health of the
Czech Republic (NT13763-4). The gift of Placebo and Omega-3 capsules by
EPAX AS, Aalesund, Norway is acknowledged. We thank Prof. Erik Richter for
the help regarding muscle biopsies and Dr. Vera Lanska for the help with
statistical analysis.
Author details
1Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
2Department of Adipose Tissue Biology, Institute of Physiology of the Czech
Academy of Sciences, Prague, Czech Republic. 3Human Development &
Health Academic Unit, Faculty of Medicine, University of Southampton,
Southampton, UK. 4Department of Mathematical Analysis and Applications of
Mathematics, Faculty of Science, Palacky University, Olomouc, Czech
Republic. 5Department of Physical Performance, Norwegian School of Sport
Sciences, Oslo, Norway. 6Silentia AS, Svelvik, Norway.
Received: 28 July 2015 Accepted: 25 November 2015
References
1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al.
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred
approach. Update to a Position Statement of the American Diabetes
Association and the European Association for the Study of Diabetes.
Diabetologia. 2015;58:429–42.
2. American DA. Standards of medical care in diabetes–2014. Diabetes Care.
2014;37 Suppl 1:S14–80.
3. Kim J, Kwak HJ, Cha JY, Jeong YS, Rhee SD, Kim KR, et al. Metformin
suppresses lipopolysaccharide (LPS)-induced inflammatory response in
murine macrophages via activating transcription factor-3 (ATF-3) induction.
J Biol Chem. 2014;289:23246–55.
4. Mirmiranpour H, Mousavizadeh M, Noshad S, Ghavami M, Ebadi M,
Ghasemiesfe M, et al. Comparative effects of pioglitazone and metformin
on oxidative stress markers in newly diagnosed type 2 diabetes patients: a
randomized clinical trial. J Diabetes Complications. 2013;27:501–7.
5. Rodriguez A, Reviriego J, Karamanos V, del Canizo FJ, Vlachogiannis N,
Drossinos V, et al. Management of cardiovascular risk factors with
pioglitazone combination therapies in type 2 diabetes: an observational
cohort study. Cardiovasc Diabetol. 2011;10:18.
6. Kus V, Flachs P, Kuda O, Bardova K, Janovska P, Svobodova M, et al.
Unmasking Differential Effects of Rosiglitazone and Pioglitazone in the
Combination Treatment with n-3 Fatty Acids in Mice Fed a High-Fat Diet.
Plos One. 2011;6:e27126–7.
7. Kuda O, Jelenik T, Jilkova Z, Flachs P, Rossmeisl M, Hensler M, et al. n-3 Fatty
acids and rosiglitazone improve insulin sensitivity through additive
stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet.
Diabetologia. 2009;52:941–51.
8. Yang J, Vallarino C, Bron M, Perez A, Liang H, Joseph G, et al. A comparison
of all-cause mortality with pioglitazone and insulin in type 2 diabetes: an
expanded analysis from a retrospective cohort study. Curr Med Res Opin.
2014;30:2223–31.
9. Anagnostis P, Karras SN. Should we stop prescribing pioglitazone? Br J Clin
Pharmacol. 2014;78:438–9.
10. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease
associated with diabetes in men and women: meta-analysis of 37
prospective cohort studies. BMJ. 2006;332:73–8.
11. Flachs P, Rossmeisl M, Kopecky J. The Effect of n-3 Fatty Acids on Glucose
Homeostasis and Insulin Sensivity. Physiol Res. 2014;63:93–118.
12. Rakhshandehroo M, Hooiveld G, Muller M, Kersten S. Comparative analysis
of gene regulation by the transcription factor PPARalpha between mouse
and human. Plos One. 2009;4:e6796.
13. Kris-Etherton PM, Harris WS, Appel LJ, Association AHANCAH. Omega-3 fatty
acids and cardiovascular disease: new recommendations from the American
Heart Association. Arterioscler Thromb Vasc Biol. 2003;23:151–2.
14. Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, et al.
Effects of purified eicosapentaenoic and docosahexaenoic acids in
nonalcoholic fatty liver disease: results from the Welcome* study.
Hepatology. 2014;60:1211–21.
15. Mozaffarian D, Lemaitre RN, King IB, Song X, Huang H, Sacks FM, et al.
Plasma phospholipid long-chain omega-3 fatty acids and total and
cause-specific mortality in older adults: a cohort study. Ann Intern Med.
2013;158:515–25.
16. Calder PC, Yaqoob P. Omega-3 (n-3) fatty acids, cardiovascular disease and
stability of atherosclerotic plaques. Cell Mol Biol (Noisy-le-Grand). 2010;56:28–37.
17. Authors/Task Force M, Ryden L, Grant PJ, Anker SD, Berne C, Cosentino F,
et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases
developed in collaboration with the EASD: the Task Force on diabetes,
pre-diabetes, and cardiovascular diseases of the European Society of
Cardiology (ESC) and developed in collaboration with the European
Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34:3035–87.
18. Kromhout D, Geleijnse JM, de Goede J, Oude Griep LM, Mulder BJ, de Boer
MJ, et al. n-3 fatty acids, ventricular arrhythmia-related events, and fatal
myocardial infarction in postmyocardial infarction patients with diabetes.
Diabetes Care. 2011;34:2515–20.
19. Dangardt F, Chen Y, Gronowitz E, Dahlgren J, Friberg P, Strandvik B. High
physiological omega-3 Fatty Acid supplementation affects muscle Fatty
Acid composition and glucose and insulin homeostasis in obese
adolescents. J Nutr Metab. 2012;2012:395757.
20. Horakova O, Medrikova D, van Schothorst EM, Bunschoten A, Flachs P, Kus
V, et al. Preservation of Metabolic Flexibility in Skeletal Muscle by a
Combined Use of n-3 PUFA and Rosiglitazone in Dietary Obese Mice. Plos
One. 2012;7:e43764.
21. Pelikanova T, Smrckova I, Krizova J, Stribrna J, Lanska V. Effects of insulin and
lipid emulsion on renal haemodynamics and renal sodium handling in
IDDM patients. Diabetologia. 1996;39:1074–82.
22. Golay A, DeFronzo RA, Ferrannini E, Simonson DC, Thorin D, Acheson K, et al.
Oxidative and non-oxidative glucose metabolism in non-obese type 2 (non-
insulin-dependent) diabetic patients. Diabetologia. 1988;31:585–91.
23. Ejsing CS, Duchoslav E, Sampaio J, Simons K, Bonner R, Thiele C, et al.
Automated identification and quantification of glycerophospholipid
molecular species by multiple precursor ion scanning. Anal Chem. 2006;78:
6202–14.
24. Kahleova H, Matoulek M, Malinska H, Oliyarnyk O, Kazdova L, Neskudla T, et al.
Vegetarian diet improves insulin resistance and oxidative stress markers more
Veleba et al. Nutrition & Metabolism  (2015) 12:52 Page 14 of 15
than conventional diet in subjects with Type 2 diabetes. Diabet Med. 2011;28:
549–59.
25. Jagadeesh B, Bharathi DV, Pankaj C, Narayana VS, Venkateswarulu V.
Development and validation of highly selective and robust method for
simultaneous estimation of pioglitazone, hydroxypioglitazone and
metformin in human plasma by LC-MS/MS: application to a
pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci.
2013;930:136–45.
26. Harris WS, Von Schacky C. The Omega-3 Index: a new risk factor for death
from coronary heart disease? Prev Med. 2004;39:212–20.
27. Galgani JE, Moro C, Ravussin E. Metabolic flexibility and insulin resistance.
Am J Physiol Endocrinol Metab. 2008;295:E1009–1017.
28. Riachi M, Himms-Hagen J, Harper ME. Percent relative cumulative frequency
analysis in indirect calorimetry: application to studies of transgenic mice.
Can J Physiol Pharmacol. 2004;82:1075–83.
29. Burdge GC, Calder PC. Plasma cytokine response during the postprandial
period: a potential causal process in vascular disease? Br J Nutr. 2005;93:3–9.
30. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect
of metformin on blood pressure, plasma cholesterol and triglycerides in
type 2 diabetes mellitus: a systematic review. J Intern Med. 2004;256:1–14.
31. Chan DC, Watts GF, Mori TA, Barrett PH, Beilin LJ, Redgrave TG. Factorial
study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral
obesity. Eur J Clin Invest. 2002;32:429–36.
32. Flachs P, Rossmeisl M, Kuda O, Kopecky J. Stimulation of mitochondrial
oxidative capacity in white fat independent of UCP1: A key to lean
phenotype. Biochim Biophys Acta. 1831;2013:986–1003.
33. Wong AT, Chan DC, Ooi EM, Ng TW, Watts GF, Barrett PH. Omega-3 fatty
acid ethyl ester supplementation decreases very-low-density lipoprotein
triacylglycerol secretion in obese men. Clin Sci (Lond). 2013;125:45–51.
34. Miles EA, Rees D, Banerjee T, Cazzola R, Lewis S, Wood R, et al. Age-related
increases in circulating inflammatory markers in men are independent of
BMI, blood pressure and blood lipid concentrations. Atherosclerosis. 2008;
196:298–305.
35. Hue L, Taegtmeyer H. The Randle cycle revisited: a new head for an old hat.
Am J Physiol Endocrinol Metab. 2009;297:E578–91.
36. Williamson JR, Kreisberg RA, Felts PW. Mechanism for the stimulation of
gluconeogenesis by fatty acids in perfused rat liver. Proc Natl Acad Sci U S
A. 1966;56:247–54.
37. Mostad IL, Bjerve KS, Basu S, Sutton P, Frayn KN, Grill V. Addition of n-3 fatty
acids to a 4-hour lipid infusion does not affect insulin sensitivity, insulin
secretion, or markers of oxidative stress in subjects with type 2 diabetes
mellitus. Metabolism. 2009;58:1753–61.
38. Mostad IL, Bjerve KS, Bjorgaas MR, Lydersen S, Grill V. Effects of n-3 fatty
acids in subjects with type 2 diabetes: reduction of insulin sensitivity and
time-dependent alteration from carbohydrate to fat oxidation. Am J Clin
Nutr. 2006;84:540–50.
39. Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, et al.
Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative
exposure analysis. Diabetologia. 2015;58:493–504.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Veleba et al. Nutrition & Metabolism  (2015) 12:52 Page 15 of 15
